AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
While it had managed to rebound from that setback, AbbVie's shares fell off a cliff late last year when one of its exciting ...
Despite the death of its golden goose, AbbVie expects to achieve high single-digit compound annual sales growth to the end of ...
Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last year.
a Represents net earnings (loss) attributable to AbbVie Inc. Intangible asset impairment reflects a partial after-tax impairment charge of $3.5 billion related to the emraclidine intangible asset ...
Also Read: AbbVie’s Early Parkinson’s Candidate Hits Primary Goal In Pivotal Late-Stage Study Despite this, the company sees potential in exploring emraclidine as an adjunctive treatment ...
So is the stock worth buying today? AbbVie had a recent setback in November when it announced poor phase 2 study results for emraclidine. The once-promising drug was a potential blockbuster for ...
after-tax impairment charge related to its investigational antipsychotic drug emraclidine that hasn't been included in management's guidance. AbbVie is one of the better pharmaceutical stocks on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results